A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study - Fangusaro, J; Onar-Thomas, A; Poussaint, T Y; Wu, S (Neuro Oncol, 2021)
et al.